Overview: OncoPro MPN Panel Test
Introduction: The OncoPro MPN Panel Test detects myeloproliferative neoplasm (MPN) mutations to diagnose MPNs, causing fatigue or clotting. Aligned with 2023 ASH guidelines, it uses PCR for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in hematology for patients with suspected MPNs, such as polycythemia vera or essential thrombocythemia.

Other Names: MPN Panel Assay, MPN Mutation Test.

FDA Status: Laboratory-developed test (LDT), meeting hematology standards for diagnostic accuracy.

Historical Milestone: MPN mutation testing began in the 2000s with JAK2 discovery. NGS methods improved in the 2010s, enhancing diagnostic precision.

Purpose: Detects MPN mutations to diagnose myeloproliferative neoplasms, guides treatment, and evaluates patients with fatigue or clotting.

Test Parameters: 1. MPN Mutations

Pretest Condition: No fasting required. Collect whole blood or bone marrow. Report history of fatigue, clotting, or MPN symptoms.

Specimen: Whole Blood (EDTA, 2-5 mL), Bone Marrow (EDTA, 2-5 mL). Transport in a biohazard container.

Sample Stability at Room Temperature: 24 hours

Sample Stability at Refrigeration: 48 hours

Sample Stability at Frozen: Not frozen

Medical History: Document fatigue, clotting, splenomegaly, or family history of MPNs. Include current medications, especially hydroxyurea.

Consent: Written consent required, detailing the tests purpose, MPN implications, and risks of sample collection.

Procedural Considerations: Uses next-generation sequencing to detect MPN mutations (e.g., JAK2, MPL). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for MPN diagnosis.

Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.

Clinical Significance: Identified mutations confirm MPNs, guiding JAK inhibitors or phlebotomy. Negative results may require bone marrow biopsy.

Specialist Consultation: Consult a hematologist or oncologist for result interpretation and treatment planning.

Additional Supporting Tests: Bone marrow biopsy, complete blood count, or JAK2 qPCR to confirm MPN diagnosis.

Test Limitations: Not all MPNs have detectable mutations; clinical correlation is needed. Sample quality affects sensitivity.

References: ASH MPN Guidelines, 2023; Blood, Tefferi A, 2022.